Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Adam Pearson used his neurofibromatosis struggles to succeed in acting and advocacy, inspiring others to accept differences ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Cupid's Undie Run sent dozens of half-naked runners through Saturday to raise awareness for a genetic disease.

Runners are encouraged to strip down to their underwear or don creative costumes to raise awareness and money for NF with ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...

A 22-month-old girl, Sophia Watson, is in urgent need of life-saving treatment for a tumor, but an insurance dispute has left her family without coverage.

The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

Last week we learned that the funding for medical research is in jeopardy. President Donald Trump’s executive order to cut ...